Stock Snapshot from
Celgene CorpAdd to My Watchlist
CELG:USNASDAQ GSIndustry: Medical-Biomedical/Gene
- 123.16Last
- 1.75 -1.40%Today's Change
- 124.91Previous Close
- 52 Week Low - High
Earnings
| EPS: Year Actual ttm | 4.128 |
| EPS: Year Est. 12/13 ttm | 5.723 |
| EPS: Quarterly Actual 3/13 | 1.37 |
| EPS: Quarterly Est. 6/13 | 1.43 |
| Price/Earnings ttm | 29.95 |
| Relative Price/Earnings | 1.828 |
| Earnings Growth Rate | 16.95 |
Company Description
| Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. | |
| Revenue | $6 billion |
| Net Income | $1 billion |
| Total Assets | $12 billion |
| Employees | 4,700 |
| Web Site | www.celgene.com |
Latest Headlines
- Merck KGaA Restructuring Boosts Stock as Drug Drought Continues
- Dow Climbs to Five-Year High as Fed Bets Offset China Concern
- Celgene’s Psoriasis Drug Helped One-Third of Patients in Study
- Monsanto Gets Support From High Court Justices on Seed Patents
- Monsanto, J.C. Penney, Elsevier, West: Intellectual Property
Watchlist
Unless indicated otherwise: intraday data is at least 15 minutes delayed; mutual fund NAVs are updated at the close of every market day; all prices are in the local currency; Time is ET.